A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 844
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : alpha-Syn
Long Form : alpha-synuclein
No. Year Title Co-occurring Abbreviation
2022 A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity. PD, SCD
2022 A New Zebrafish Model to Measure Neuronal α-Synuclein Clearance In Vivo. DLB, MSA, PD, WT
2022 A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine. CSF, PD
2022 Akkermansia muciniphila induces mitochondrial calcium overload and α -synuclein aggregation in an enteroendocrine cell line. CCK, EEC, PD
2022 Alpha-Synuclein Aggregation Pathway in Parkinson's Disease: Current Status and Novel Therapeutic Approaches. PD
2022 Alpha-Synuclein Autoimmune Decline in Prodromal Multiple System Atrophy and Parkinson's Disease. Ig, NAbs, PD
2022 Alpha-Synuclein Clearance through Inhibiting Akt/mTOR Pathway by Microfluidic Encapsulated Induced Conjunctival MSCs in a Parkinsonian Model. 6-OHDA, CJ-MSCs, GFP, MFB, miR-149, MSCs, PD, qRT-PCR
2022 Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction. mEPSCs, qEPSCs, SNAP23, SNAREs, TA
2022 Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo. NAbs, nAbs-alphaSyn, PD
10  2022 AMPK-dependent autophagy activation and alpha-Synuclein clearance: a putative mechanism behind alpha-mangostin's neuroprotection in a rotenone-induced mouse model of Parkinson's disease. AM, AMPK, PD
11  2022 An Isogenic Collection of Pluripotent Stem Cell Lines With Elevated α-Synuclein Expression Validated for Neural Induction and Cortical Neuron Differentiation. DLB, hiPSCs, PD
12  2022 Anti-α-synuclein Toxicity and Anti-neurodegenerative Role of Chrysin in Transgenic Caenorhabditis elegans Models of Parkinson's Disease. DA, PD
13  2022 APOE4 exacerbates α-synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology. AD, FPLC, iPSC, LBD, RT-QuIC, SEC
14  2022 Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies. ---
15  2022 Biomarkers Related to Synaptic Dysfunction to Discriminate Alzheimer's Disease from Other Neurological Disorders. Ng
16  2022 Change in the Oligomeric State of α-Synuclein Variants in Living Cells. PD
17  2022 Charge detection mass spectrometry on human-amplified fibrils from different synucleinopathies. CDMS, DLB, PD, RT-QuIC
18  2022 Clinical application of prion-like seeding in α-synucleinopathies: Early and non-invasive diagnosis and therapeutic development. ---
19  2022 Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again. CBD, CSF, CSs, MSA, NfL, PD, PSP
20  2022 Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms. PD, PTMs
21  2022 Conformation-Dependent Influences of Hydrophobic Amino Acids in Two In-Register Parallel β-Sheet Amyloids, an α-Synuclein Amyloid and a Local Structural Model of PrPSc. MD
22  2022 Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation. PD
23  2022 CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology. Abeta42, AD, ANCOVAs, AUC, CI, CSF, MMSE, Ng, t-tau
24  2022 Curcumin Interacts with α-Synuclein Condensates To Inhibit Amyloid Aggregation under Phase Separation. PD
25  2022 De novo designed protein inhibitors of amyloid aggregation and seeding. AD, PD
26  2022 Design and Development of Benzothiazole-Based Fluorescent Probes for Selective Detection of Aβ Aggregates in Alzheimer's Disease. AD, BSA
27  2022 Design of typical genes for heterologous gene expression. GFP
28  2022 Development of an extended half-life GM-CSF fusion protein for Parkinson's disease. GM-CSF, MPTP, PD, Teff to Treg
29  2022 Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis. CIs, CSF, SAAs
30  2022 Different patterns of exosomal α-synuclein between Parkinson's disease and probable rapid eye movement sleep behavior disorder. HCs, iRBD, n-exo alpha-Syn, PD, pRBD, t-exo alpha-Syn
31  2022 Direct Demonstration of Seed Size-Dependent α-Synuclein Amyloid Amplification. ---
32  2022 Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease. LRP, PD, PLA
33  2022 Dopamine D3 Receptor in Parkinson Disease: A Prognosis Biomarker and an Intervention Target. BDNF, D1R, D2R, D3R, DA, L-dopa, PD
34  2022 Dynamical Behavior of Disordered Regions in Disease-Related Proteins Revealed by Quasielastic Neutron Scattering. FCM, IDPs, IDRs, QENS, Tn-CD
35  2022 Early Signs of Molecular Defects in iPSC-Derived Neural Stems Cells from Patients with Familial Parkinson's Disease. PD
36  2022 Effect of olfactory bulb pathology on olfactory function in normal aging. OB, UPSIT
37  2022 Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies. ---
38  2022 Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies. DLB, PD
39  2022 Efficient Entrapment of Alpha-Synuclein Biotinylated Antibody in KCC-1-NH-CS2 and Application for the Sensitive Diagnosis of Parkinson's Using Recognition of Biomarker: An Innovative Electrochemical Label-Free Immunosensor for the Biomedical Analysis of Neurodegenerative Diseases. PD
40  2022 Evidence of Inflammation in Parkinson's Disease and Its Contribution to Synucleinopathy. PD
41  2022 Evolution of α-synuclein conformation ensemble toward amyloid fibril via liquid-liquid phase separation (LLPS) as investigated by dynamic nuclear polarization-enhanced solid-state MAS NMR. cryo-EM, DNP, LLPS, MAS, NMR
42  2022 Examination of Abnormal Alpha-synuclein Aggregates in the Enteric Neural Plexus in Patients with Ulcerative Colitis. PD, UC
43  2022 Exogenous human α-Synuclein acts in vitro as a mild platelet antiaggregant inhibiting α-thrombin-induced platelet activation. PD
44  2022 Fine Particulate Matter Triggers α-Synuclein Fibrillization and Parkinson-like Neurodegeneration. PD
45  2022 Functional Cooperation of α-Synuclein and Tau Is Essential for Proper Corticogenesis. ---
46  2022 Functional Screening of Parkinson's Disease Susceptibility Genes to Identify Novel Modulators of α-Synuclein Neurotoxicity in Caenorhabditis elegans. CEP, DA, PD, RNAi
47  2022 Gene Co-expression Analysis of the Human Substantia Nigra Identifies ZNHIT1 as an SNCA Co-expressed Gene that Protects Against α-Synuclein-Induced Impairments in Neurite Growth and Mitochondrial Dysfunction in SH-SY5Y Cells. PD, SN, ZNHIT1
48  2022 Generating Ensembles of Dynamic Misfolding Proteins. beta2m, IDP
49  2022 Glutamatergic transmission and receptor expression in the synucleinopathy h-α-synL62 mouse model: Effects of hydromethylthionine. DLB, HMTM, mGluR5, MTEP, NMDA, PD
50  2022 High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson's disease. iPSC
51  2022 High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification. iPSCs, mDAn, ML, PD
52  2022 Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy. BDNF, h-alpha-Syn, IND-ASO, PD
53  2022 Icaritin attenuates 6-OHDA-induced MN9D cell damage by inhibiting oxidative stress. HO-1, ICT, Nrf2, ROS, SOD, TH
54  2022 Identification of exosomal biomarkers and its optimal isolation and detection method for the diagnosis of Parkinson's disease: A systematic review and meta-analysis. CI, PD, REML, RoM
55  2022 Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein. DLB, PD
56  2022 Improved method for preparation and purification of recombinant α-synuclein: high-mannose-type free N-glycan prepared from an edible bean (Vigna angulari, Azuki bean) inhibits α-synuclein aggregation. ---
57  2022 In vivo imaging of alpha-synuclein with antibody-based PET. MSA, PD, PET, TfR
58  2022 Inhibition of Wnt/β-catenin signaling attenuates axonal degeneration in models of Parkinson's disease. 3-MA, DKK1, GSK-3beta, p-beta-catenin, PD
59  2022 Lactobacillus plantarum DP189 Reduces α-SYN Aggravation in MPTP-Induced Parkinson's Disease Mice via Regulating Oxidative Damage, Inflammation, and Gut Microbiota Disorder. IL-10, IL-1beta, IL-6, MDA, MPTP, Nrf2, PD, ROS, SN, SOD, TNF-alpha
60  2022 Lewy body disease or diseases with Lewy bodies? DLB, LBD, LBs, PD, PDD
61  2022 Lewy Body Disease Primate Model with α-Synuclein Propagation from the Olfactory Bulb. LBDs, OB
62  2022 Linking the phenotype of SNCA Triplication with PET-MRI imaging pattern and alpha-synuclein CSF seeding. PD, SNCA
63  2022 Lipid Species Dependent Vesicles Clustering Caused by alpha-Synuclein as Revealed by Single-Vesicle Imaging with Total Internal Reflection Fluorescence Microscopy. TIRF
64  2022 Long-term inhibition of mutant LRRK2 hyper-kinase activity reduced mouse brain α-synuclein oligomers without adverse effects. ACR, PD, WT
65  2022 LRP1 is a neuronal receptor for α-synuclein uptake and spread. AAVs, iPSCs, iPSNs, LBD, LRP1, LRP1-KO, Lrp1-nKO, PD, PFFs, WT
66  2022 LRRK2 Inhibition Mitigates the Neuroinflammation Caused by TLR2-Specific α-Synuclein and Alleviates Neuroinflammation-Derived Dopaminergic Neuronal Loss. IPD, LRRK2, PD, TLR2
67  2022 Lysophosphatidylcholine acyltransferase 1 promotes pathology and toxicity in two distinct cell-based alpha-synuclein models. LPCAT1, PFF
68  2022 Lysosomal exocytosis releases pathogenic α-synuclein species from neurons in synucleinopathy models. ---
69  2022 Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease. MC1R, Nrf2, PD
70  2022 Mesenchymal stem cell-derived exosomes altered neuron cholesterol metabolism via Wnt5a-LRP1 axis and alleviated cognitive impairment in a progressive Parkinson's disease model. BMSCinduced-EXO, BMSCquiescent-EXO, LC/MS, PC, PD, PE, PG, PI, PS, WT
71  2022 Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson's Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice. DA, MPH, PD, Syn III, Tg
72  2022 MicroRNA miR-7 Is Essential for Post-stroke Functional Recovery. ---
73  2022 Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications. DA, PD
74  2022 Myricetin Inhibits α-Synuclein Amyloid Aggregation by Delaying the Liquid-to-Solid Phase Transition. LLPS, PD
75  2022 Neuropathology of α-synuclein in Parkinson's disease. LBs, PD
76  2022 Neuroprotective Effects of a Novel Demeclocycline Derivative Lacking Antibiotic Activity: From a Hit to a Promising Lead Compound. alpha-SynPFF, DMC
77  2022 Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson's disease. CBD, CNS, DA, PD, SNpc
78  2022 Neuroprotective effects of indole-3-carbinol on the rotenone rat model of Parkinson's disease: Impact of the SIRT1-AMPK signaling pathway. DA, I3C, PD, ROT, TH
79  2022 Neurotoxicity of pesticides - A link to neurodegeneration. MB, MPTP, OC, PD, PQ
80  2022 Novel insights into the role of circular RNAs in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases. circRNAs, miRNAs, PD
81  2022 NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-α-synuclein mouse model of Parkinson's disease. PD, SN
82  2022 Oral Mucosa Derived α-Synuclein as a Potential Diagnostic Biomarker for Parkinson's Disease. AUC, CNS, PD, pS129
83  2022 Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons. ---
84  2022 Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity. FRET-CLEM, iPSC, PD, ROS, smFRET
85  2022 Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. LBD
86  2022 Phosphatidylcholine and Phosphatidylserine Uniquely Modify the Secondary Structure of α-Synuclein Oligomers Formed in Their Presence at the Early Stages of Protein Aggregation. AFM-IR
87  2022 Phosphorylated alpha-synuclein in Iba1-positive macrophages in the skin of patients with Parkinson's disease. IPD, palphaSyn
88  2022 Raman Spectroscopy Study of Skin Biopsies from Patients with Parkinson's Disease: Trends in Alpha-Synuclein Aggregation from the Amide I Region. DFT, PD
89  2022 Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein. DLB, mAbs, MSA, PD, PFFs, SPR
90  2022 Real-Time Quaking- Induced Conversion Assays for Prion Diseases, Synucleinopathies, and Tauopathies. RT-QuIC
91  2022 Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. ---
92  2022 Reelin protects against pathological α-synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson's disease. EE, LAMP1, PD, PFF
93  2022 Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model. PD, PREP
94  2022 Restricting α-synuclein transport into mitochondria by inhibition of α-synuclein-VDAC complexation as a potential therapeutic target for Parkinson's disease treatment. PD, VDAC
95  2022 Roles of α-Synuclein and Disease-Associated Factors in Drosophila Models of Parkinson's Disease. PD
96  2022 Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome. beta-GCase, CatD, HEXB, PD, PSAP
97  2022 SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro. PD
98  2022 Single residue modulators of amyloid formation in the N-terminal P1-region of α-synuclein. ---
99  2022 Single-Particle Resolution of Copper-Associated Annular α-Synuclein Oligomers Reveals Potential Therapeutic Targets of Neurodegeneration. AFM
100  2022 Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse Aβ plaque pathology when injected into newborn mouse hosts. AD, APP, CAA, LBD